Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (PACB)
NASDAQ:PACB
PACB Stock Chart & Stats
$1.78
$0.14(7.00%)
At close: 4:00 PM EST
$1.78
$0.14(7.00%)
Day’s Range― - ―
52-Week Range$0.85 - $2.72
Previous CloseN/A
Volume8.28M
Average Volume (3M)9.28M
Market Cap
$600.74M
Enterprise ValueN/A
Total Cash (Recent Filing)$314.74M
Total Debt (Recent Filing)$699.22M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Feb 12, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding300,370,600
10 Day Avg. Volume11,567,733
30 Day Avg. Volume9,279,151
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)0.99
Price to Sales (P/S)3.26
P/FCF Ratio-2.37
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$2.08Price Target Upside16.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Customer AdoptionPacBio's systems are gaining clinical uptake, with a third of Revios shipped to labs.
Financial PerformanceRevenue for 2Q25 was 9% above consensus estimates, indicating strong performance.
Product InnovationThe new SPRQ-Nx chemistry and multi-use SMRT cells will enable a nearly 40% reduction in cost to $300 per 20x genome on Revio compared to original SPRQ chemistry and SMRT cells.
Bears Say
Market ConditionsThe macro environment continues to weigh on guidance, though there is potential upside.
Pricing PressureThe performance was impacted by lower Revio pricing and delayed Vega shipments.
Revenue GuidanceThe company narrowed its 2025 revenue guidance, lowering the midpoint, due to ongoing NIH budget uncertainty and lower-than-expected placements.
Pacific Biosciences News
PACB FAQ
What was Pacific Biosciences’s price range in the past 12 months?
Pacific Biosciences lowest stock price was $0.85 and its highest was $2.72 in the past 12 months.
What is Pacific Biosciences’s market cap?
Pacific Biosciences’s market cap is $600.74M.
When is Pacific Biosciences’s upcoming earnings report date?
Pacific Biosciences’s upcoming earnings report date is Feb 12, 2026 which is in 96 days.
How were Pacific Biosciences’s earnings last quarter?
Pacific Biosciences released its earnings results on Nov 05, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.151 by $0.021.
Is Pacific Biosciences overvalued?
According to Wall Street analysts Pacific Biosciences’s price is currently Undervalued.
Does Pacific Biosciences pay dividends?
Pacific Biosciences does not currently pay dividends.
What is Pacific Biosciences’s EPS estimate?
Pacific Biosciences’s EPS estimate is -0.15.
How many shares outstanding does Pacific Biosciences have?
Pacific Biosciences has 300,370,600 shares outstanding.
What happened to Pacific Biosciences’s price movement after its last earnings report?
Pacific Biosciences reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.151. Following the earnings report the stock price went down -7.292%.
Which hedge fund is a major shareholder of Pacific Biosciences?
Currently, no hedge funds are holding shares in PACB
Pacific Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.08 (16.85% Upside)
$2.08 (16.85% Upside)
Blogger Sentiment
Bearish
PACB Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $35.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 11.0%
Last 30 Days ▲ 11.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.90%
12-Months-Change
Fundamentals
Return on Equity
-205.41%
Trailing 12-Months
Asset Growth
-45.31%
Trailing 12-Months
Company Description
Pacific Biosciences
Pacific Biosciences (PACB) is a biotechnology company specializing in the development and commercialization of advanced sequencing technologies for genomic research. Founded in 2004 and headquartered in Menlo Park, California, PACB focuses on providing high-throughput, long-read sequencing solutions that enable researchers to analyze complex genomes with unprecedented accuracy. Its core products include the Sequel II and Sequel IIe Systems, which are designed for a wide range of applications, from basic research to clinical genomics, and support various fields such as agriculture, human health, and environmental science.
PACB Company Deck
PACB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive and negative aspects. While there were significant achievements in consumable revenue, gross margin improvements, and clinical advancements, these were tempered by an overall decline in total revenue and challenges in the funding environment impacting instrument sales.View all PACB earnings summariesPACB Stock 12 Month Forecast
Average Price Target
$2.08
▲(16.85% Upside)
Technical Analysis
Ownership Overview
2.39% Insiders
8.39% Mutual Funds
1.44% Other Institutional Investors
68.35% Public Companies and Individual Investors